The FDA has approved an HIV dual therapy developed by GSK’s specialist joint venture, ViiV Healthcare, a convenient combination that will compete with Gilead's nearly-approved three-drug re
GlaxoSmithKline saw its share price fall 6% yesterday after releasing underwhelming figures in Q3, and leaving investors uncertain about its future dividend payments.
